Xgene Pharmaceutical_Life Sciences_YIJING CAPITAL

Xgene Pharmaceutical
Xgene Pharmaceutical develops improved innovative drugs for major conditions including pain, seeking both clinical value and commercialization potential. Its lead oral nonopioid analgesic XG005 has secured a business development (BD) partnership. The company continues R&D and clinical translation of improved medicines to provide safer, more effective pain treatments
Xgene Pharmaceutical
We Look Forward to Hearing from You
Discovering talent, investing in the future, and growing with visionary entrepreneurs

Submit BP

Yijing Capital focuses on innovative companies in frontier technology, life sciences, and related fields. Please complete the basic project information and upload the latest version of your business plan (BP). Our investment team will evaluate the materials and contact projects that align with our investment focus.

All submitted materials will be used solely for investment evaluation. We will strictly protect your business information.

Thank you for your trust in Yijing Capital.
We have received your business plan. After completing an initial evaluation, our investment team will contact projects that align with our investment focus. Due to the volume of submissions, we appreciate your understanding if you do not receive a follow-up. We wish your project every success!

OK